Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Average Recommendation of "Buy" from Analysts

Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX - Get Free Report) have received an average recommendation of "Buy" from the nine ratings firms that are covering the company, MarketBeat Ratings reports. Eight equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $40.57.

A number of equities research analysts have recently issued reports on PLRX shares. HC Wainwright restated a "buy" rating and issued a $38.00 target price on shares of Pliant Therapeutics in a research note on Friday, November 8th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Pliant Therapeutics in a research note on Thursday, August 8th. Leerink Partnrs upgraded shares of Pliant Therapeutics to a "strong-buy" rating in a research note on Monday, September 9th. Needham & Company LLC reiterated a "buy" rating and set a $38.00 price objective on shares of Pliant Therapeutics in a research note on Thursday, August 8th. Finally, Oppenheimer dropped their price objective on shares of Pliant Therapeutics from $48.00 to $45.00 and set an "outperform" rating on the stock in a research note on Thursday, August 8th.

Institutional Investors Weigh In On Pliant Therapeutics

Several large investors have recently made changes to their positions in PLRX. Summit Securities Group LLC acquired a new stake in shares of Pliant Therapeutics in the second quarter valued at approximately $59,000. Atria Investments Inc acquired a new stake in shares of Pliant Therapeutics in the third quarter valued at approximately $112,000. Deerfield Management Company L.P. Series C acquired a new stake in shares of Pliant Therapeutics in the second quarter valued at approximately $126,000. China Universal Asset Management Co. Ltd. increased its stake in shares of Pliant Therapeutics by 65.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 11,694 shares of the company's stock valued at $131,000 after purchasing an additional 4,607 shares during the period. Finally, Intech Investment Management LLC acquired a new stake in shares of Pliant Therapeutics in the third quarter valued at approximately $145,000. Institutional investors and hedge funds own 97.30% of the company's stock.

Pliant Therapeutics Stock Up 1.4 %

Shares of Pliant Therapeutics stock traded up $0.19 during trading on Thursday, reaching $13.53. The company had a trading volume of 333,273 shares, compared to its average volume of 458,086. The company has a market cap of $823.35 million, a price-to-earnings ratio of -4.05 and a beta of 1.08. The firm's fifty day moving average is $13.20 and its 200-day moving average is $12.76. The company has a debt-to-equity ratio of 0.09, a quick ratio of 10.26 and a current ratio of 10.26. Pliant Therapeutics has a fifty-two week low of $10.22 and a fifty-two week high of $19.62.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.